afatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	4318	850140-72-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: afatinib tovok afatinib dimaleate gilotrif BIBW2992 afatinib maleate	A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER. Molecular weight: 485.94 Formula: C24H25ClFN5O3 CLOGP: 4.34 LIPINSKI: 0 HAC: 8 HDO: 2 TPSA: 88.61 ALOGS: -4.58 ROTB: 8 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

afatinib
tovok
afatinib dimaleate
gilotrif
BIBW2992
afatinib maleate

A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER.

Molecular weight: 485.94
Formula: C24H25ClFN5O3
CLOGP: 4.34
LIPINSKI: 0
HAC: 8
HDO: 2
TPSA: 88.61
ALOGS: -4.58
ROTB: 8

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
40	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Hosey CM, Chan R, Benet LZ
S (Water solubility)	14.36 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Sept. 25, 2013	EMA
July 12, 2013	FDA	BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1866.95	28.61	616	8301	81505	63398600
Diarrhoea	1250.20	28.61	917	8000	714449	62765656
Paronychia	796.22	28.61	179	8738	5386	63474719
Metastases to central nervous system	346.55	28.61	111	8806	12994	63467111
Stomatitis	273.07	28.61	194	8723	138531	63341574
Dermatitis acneiform	225.77	28.61	64	8853	4932	63475173
Rash	220.74	28.61	327	8590	560544	62919561
Decreased appetite	182.16	28.61	199	8718	250853	63229252
Metastases to meninges	157.72	28.61	42	8875	2560	63477545
Dehydration	153.50	28.61	153	8764	173201	63306904
Skin toxicity	145.63	28.61	45	8872	4669	63475436
EGFR gene mutation	115.96	28.61	22	8895	275	63479830
Acne	100.82	28.61	54	8863	23239	63456866
Pleural effusion	87.39	28.61	85	8832	93125	63386980
Dry skin	85.80	28.61	68	8849	56819	63423286
Drug resistance	71.75	28.61	43	8874	22890	63457215
Skin fissures	65.53	28.61	32	8885	11356	63468749
Metastases to bone	64.69	28.61	39	8878	20980	63459125
Mucosal inflammation	64.20	28.61	53	8864	46875	63433230
Vomiting	63.41	28.61	197	8720	559420	62920685
Death	62.49	28.61	152	8765	374229	63105876
Skin disorder	59.50	28.61	42	8875	29465	63450640
Nail disorder	58.63	28.61	31	8886	12984	63467121
Metastases to liver	58.02	28.61	38	8879	23601	63456504
Interstitial lung disease	51.61	28.61	53	8864	61855	63418250
Metastases to lung	50.82	28.61	28	8889	12722	63467383
Acquired gene mutation	50.82	28.61	14	8903	969	63479136
Therapy partial responder	49.75	28.61	26	8891	10632	63469473
Small cell lung cancer	47.81	28.61	15	8902	1634	63478471
Arthralgia	45.51	28.61	12	8905	569698	62910407
Disease progression	41.33	28.61	67	8850	122691	63357414
Cutaneous symptom	39.57	28.61	9	8908	283	63479822
Gene mutation	39.48	28.61	13	8904	1652	63478453
Epistaxis	38.13	28.61	49	8868	72676	63407429
Onychoclasis	37.34	28.61	18	8899	6204	63473901
Nausea	35.16	28.61	222	8695	854249	62625856
Condition aggravated	35.01	28.61	7	8910	402210	63077895
Pneumonitis	34.62	28.61	33	8884	35189	63444916
Oral pain	34.56	28.61	30	8887	28364	63451741
Neoplasm progression	31.82	28.61	32	8885	36396	63443709
Rash pustular	31.82	28.61	17	8900	7265	63472840
Prerenal failure	31.40	28.61	11	8906	1685	63478420
Pain	30.08	28.61	36	8881	740592	62739513

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1324.12	33.74	474	4096	87572	34864789
Diarrhoea	592.40	33.74	447	4123	389465	34562896
Paronychia	357.39	33.74	84	4486	3321	34949040
Metastases to central nervous system	279.75	33.74	83	4487	8122	34944239
Rash	262.21	33.74	222	4348	222530	34729831
Stomatitis	228.15	33.74	111	4459	42403	34909958
EGFR gene mutation	128.94	33.74	22	4548	155	34952206
Dermatitis acneiform	113.11	33.74	39	4531	6150	34946211
Interstitial lung disease	92.68	33.74	73	4497	65209	34887152
Decreased appetite	87.63	33.74	108	4462	166284	34786077
Skin toxicity	60.59	33.74	23	4547	4761	34947600
Acne	53.54	33.74	27	4543	11039	34941322
Lymphangiosis carcinomatosa	52.56	33.74	14	4556	918	34951443
Metastases to bone	51.53	33.74	27	4543	11943	34940418
Metastases to meninges	50.74	33.74	15	4555	1439	34950922
Pleural effusion	46.12	33.74	55	4515	81491	34870870
Dehydration	44.99	33.74	69	4501	129900	34822461
Drug resistance	34.58	33.74	28	4542	25899	34926462
Nail disorder	33.74	33.74	12	4558	2067	34950294

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	2677.53	24.52	936	11333	135054	79597065
Diarrhoea	1567.22	24.52	1185	11084	879304	78852815
Paronychia	1029.56	24.52	239	12030	7569	79724550
Metastases to central nervous system	474.62	24.52	152	12117	16223	79715896
Stomatitis	440.15	24.52	276	11993	146481	79585638
Rash	415.73	24.52	475	11794	577883	79154236
Dermatitis acneiform	323.63	24.52	101	12168	9892	79722227
EGFR gene mutation	245.24	24.52	45	12224	419	79731700
Decreased appetite	227.50	24.52	271	11998	342147	79389972
Metastases to meninges	184.84	24.52	52	12217	3549	79728570
Skin toxicity	183.94	24.52	63	12206	8251	79723868
Dehydration	152.39	24.52	189	12080	247998	79484121
Acne	128.76	24.52	69	12200	27121	79704998
Interstitial lung disease	116.61	24.52	113	12156	112487	79619632
Pleural effusion	109.53	24.52	123	12146	145139	79586980
Metastases to bone	101.86	24.52	57	12212	24370	79707749
Dry skin	89.35	24.52	78	12191	67917	79664202
Drug resistance	89.06	24.52	64	12205	42149	79689970
Metastases to liver	86.40	24.52	54	12215	28260	79703859
Lymphangiosis carcinomatosa	74.87	24.52	23	12246	2131	79729988
Therapy partial responder	73.63	24.52	41	12228	17356	79714763
Nail disorder	73.25	24.52	36	12233	11816	79720303
Small cell lung cancer	72.27	24.52	24	12245	2856	79729263
Skin fissures	67.04	24.52	35	12234	13038	79719081
Metastases to lung	64.02	24.52	38	12231	18125	79713994
Vomiting	62.45	24.52	234	12035	665594	79066525
Mucosal inflammation	62.09	24.52	67	12202	75513	79656606
Gene mutation	58.02	24.52	20	12249	2666	79729453
Acquired gene mutation	57.60	24.52	19	12250	2214	79729905
Skin disorder	52.94	24.52	43	12226	33900	79698219
Rash pustular	48.80	24.52	27	12242	11284	79720835
Cutaneous symptom	47.72	24.52	12	12257	530	79731589
Death	43.32	24.52	187	12082	566327	79165792
Arthralgia	43.24	24.52	17	12252	571786	79160333
Nausea	39.72	24.52	267	12002	956929	78775190
Condition aggravated	39.38	24.52	14	12255	501110	79231009
Malignant neoplasm of pleura	37.86	24.52	8	12261	161	79731958
Onychoclasis	34.63	24.52	17	12252	5561	79726558
Neoplasm progression	34.25	24.52	41	12228	51641	79680478
Epistaxis	33.61	24.52	61	12208	111454	79620665
Disease progression	32.47	24.52	81	12188	184281	79547838
Drug ineffective	31.92	24.52	75	12194	1080838	78651281
Metastases to pleura	31.36	24.52	11	12258	1543	79730576
Lung adenocarcinoma	29.15	24.52	17	12252	7847	79724272
Pneumonitis	28.95	24.52	41	12228	60819	79671300
Drug interaction	28.73	24.52	14	12255	415169	79316950
Gastrointestinal toxicity	28.66	24.52	17	12252	8092	79724027
Prerenal failure	28.25	24.52	13	12256	3685	79728434
Dysgeusia	27.91	24.52	39	12230	57138	79674981
Small cell carcinoma	27.58	24.52	7	12262	321	79731798
Product dose omission issue	27.51	24.52	3	12266	247534	79484585
Pain	26.69	24.52	42	12227	703760	79028359
Cheilitis	26.52	24.52	14	12255	5327	79726792
Malignant transformation	26.04	24.52	9	12260	1209	79730910
Angular cheilitis	25.90	24.52	8	12261	754	79731365
Metastasis	25.83	24.52	15	12254	6865	79725254
Toxicity to various agents	25.19	24.52	17	12252	421523	79310596
Joint swelling	24.53	24.52	7	12262	288639	79443480

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EB03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
FDA MoA	N0000175076	Protein Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:38637	tyrosine kinase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Non-small cell lung cancer, positive for epidermal growth factor receptor expression	indication	426964009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.1	acidic
pKa2	8.94	Basic
pKa3	4.09	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	9539258	Nov. 9, 2026	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	9539258	Nov. 9, 2026	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
EQ 40MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	9539258	Nov. 9, 2026	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	April 15, 2023	TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	April 15, 2023	TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
EQ 40MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	April 15, 2023	TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Oct. 15, 2023	PEDIATRIC EXCLUSIVITY
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Oct. 15, 2023	PEDIATRIC EXCLUSIVITY
EQ 40MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Oct. 15, 2023	PEDIATRIC EXCLUSIVITY
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Jan. 12, 2025	FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Jan. 12, 2025	FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
EQ 40MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Jan. 12, 2025	FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	April 7, 2025	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTSFROM CLINICAL STUDY 1200.120, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	April 7, 2025	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTSFROM CLINICAL STUDY 1200.120, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
EQ 40MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	April 7, 2025	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTSFROM CLINICAL STUDY 1200.120, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	July 12, 2025	PEDIATRIC EXCLUSIVITY
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	July 12, 2025	PEDIATRIC EXCLUSIVITY
EQ 40MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	July 12, 2025	PEDIATRIC EXCLUSIVITY
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Oct. 7, 2025	PEDIATRIC EXCLUSIVITY
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Oct. 7, 2025	PEDIATRIC EXCLUSIVITY
EQ 40MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Oct. 7, 2025	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	INHIBITOR	Kd	10	CHEMBL	CHEMBL
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN	INHIBITOR	Kd	8.20	CHEMBL	CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	INHIBITOR	Kd	8.30	CHEMBL	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	6.24	CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		Kd	5.85	CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Kinase	P15735	PHKG2_HUMAN		Kd	6.33	CHEMBL
Myosin light chain kinase, smooth muscle	Kinase	Q15746	MYLK_HUMAN		Kd	4.50	CHEMBL
Tyrosine-protein kinase HCK	Kinase	P08631	HCK_HUMAN		Kd	5.66	CHEMBL
Mitogen-activated protein kinase 10	Kinase	P53779	MK10_HUMAN		Kd	5.70	CHEMBL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN		Kd	5.66	CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Kinase	Q16816	PHKG1_HUMAN		Kd	5.89	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	5.37	CHEMBL
Mitogen-activated protein kinase 11	Kinase	Q15759	MK11_HUMAN		Kd	5.55	CHEMBL
Serine/threonine-protein kinase 17A	Kinase	Q9UEE5	ST17A_HUMAN		Kd	5.64	CHEMBL
Ephrin type-A receptor 6	Kinase	Q9UF33	EPHA6_HUMAN		Kd	6.47	CHEMBL
Casein kinase I isoform epsilon	Kinase	P49674	KC1E_HUMAN		Kd	5.89	CHEMBL
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		Kd	5.89	CHEMBL
Tyrosine-protein kinase FRK	Kinase	P42685	FRK_HUMAN		Kd	5.85	CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN		Kd	7.10	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	5.57	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	5.43	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2	Kinase	Q9HBH9	MKNK2_HUMAN		Kd	5.80	CHEMBL
Mitogen-activated protein kinase 9	Kinase	P45984	MK09_HUMAN		Kd	5.68	CHEMBL
MAP kinase-activated protein kinase 2	Kinase	P49137	MAPK2_HUMAN		Kd	6.09	CHEMBL
Tyrosine-protein kinase receptor UFO	Kinase	P30530	UFO_HUMAN		Kd	5.28	CHEMBL
Ribosomal protein S6 kinase alpha-6	Kinase	Q9UK32	KS6A6_HUMAN		Kd	5.51	CHEMBL
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN		Kd	5.51	CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Kinase	Q9Y463	DYR1B_HUMAN		Kd	5.55	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1	Kinase	Q9BUB5	MKNK1_HUMAN		Kd	5.74	CHEMBL
Tyrosine-protein kinase Blk	Kinase	P51451	BLK_HUMAN		Kd	6.66	CHEMBL
Citron Rho-interacting kinase	Kinase	O14578	CTRO_HUMAN		Kd	5.54	CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Kinase	Q13627	DYR1A_HUMAN		Kd	6.01	CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2	Kinase	Q92630	DYRK2_HUMAN		Kd	5.74	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	5.51	CHEMBL
Homeodomain-interacting protein kinase 4	Kinase	Q8NE63	HIPK4_HUMAN		Kd	6.44	CHEMBL
Interleukin-1 receptor-associated kinase 1	Kinase	P51617	IRAK1_HUMAN		Kd	6.62	CHEMBL
Receptor tyrosine-protein kinase erbB-3	Kinase	P21860	ERBB3_HUMAN		Kd	5.35	CHEMBL
Serine/threonine-protein kinase SBK1	Kinase	Q52WX2	SBK1_HUMAN		Kd	5.32	CHEMBL
Adenosine kinase	Kinase	P55263	ADK_HUMAN		Kd	5.46	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	5.89	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	6.64	CHEMBL
Proto-oncogene tyrosine-protein kinase Src	Kinase	P12931	SRC_HUMAN		Kd	5.55	CHEMBL

External reference:

ID	Source
4032662	VUID
N0000188388	NUI
D09724	KEGG_DRUG
850140-73-7	SECONDARY_CAS_RN
4032662	VANDF
4032663	VANDF
C2987648	UMLSCUI
CHEBI:61390	CHEBI
0WM	PDB_CHEM_ID
CHEMBL1173655	ChEMBL_ID
D000077716	MESH_DESCRIPTOR_UI
DB08916	DRUGBANK_ID
5667	IUPHAR_LIGAND_ID
9230	INN_ID
41UD74L59M	UNII
10184653	PUBCHEM_CID
1430268	RXNORM
204142	MMSL
29566	MMSL
d08113	MMSL
015117	NDDF
015118	NDDF
703579002	SNOMEDCT_US
703580004	SNOMEDCT_US
703582007	SNOMEDCT_US
CHEMBL2105712	ChEMBL_ID
CHEMBL2347958	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0137	TABLET, FILM COATED	30 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0137	TABLET, FILM COATED	30 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0137	TABLET, FILM COATED	30 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0138	TABLET, FILM COATED	40 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0138	TABLET, FILM COATED	40 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0138	TABLET, FILM COATED	40 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0141	TABLET, FILM COATED	20 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0141	TABLET, FILM COATED	20 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0141	TABLET, FILM COATED	20 mg	ORAL	NDA	31 sections